China Resources Boya Bio pharmaceutical Group Co Ltd (300294) - Total Liabilities
Based on the latest financial reports, China Resources Boya Bio pharmaceutical Group Co Ltd (300294) has total liabilities worth CN¥942.80 Million CNY (≈ $137.96 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of China Resources Boya Bio pharmaceutical 's assets are long-term investments to see how much of total assets are deployed in long-term investments.
China Resources Boya Bio pharmaceutical Group Co Ltd - Total Liabilities Trend (2008–2025)
This chart illustrates how China Resources Boya Bio pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is China Resources Boya Bio pharmaceutical 's balance sheet.
China Resources Boya Bio pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of China Resources Boya Bio pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dongwon Ind
KO:006040
|
Korea | ₩4.13 Trillion |
|
Metsa Board Oyj B
HE:METSB
|
Finland | €1.14 Billion |
|
AcadeMedia AB (publ)
ST:ACAD
|
Sweden | Skr16.12 Billion |
|
Asseco South Eastern Europe S.A.
WAR:ASE
|
Poland | zł1.30 Billion |
|
Shenzhen United Winners Laser Co Ltd
SHG:688518
|
China | CN¥4.62 Billion |
|
Evergreen Steel Corp
TW:2211
|
Taiwan | NT$8.16 Billion |
|
Fengfan Power
SHG:601700
|
China | CN¥4.80 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥823.87 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down China Resources Boya Bio pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 300294 equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how China Resources Boya Bio pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for China Resources Boya Bio pharmaceutical Group Co Ltd (2008–2025)
The table below shows the annual total liabilities of China Resources Boya Bio pharmaceutical Group Co Ltd from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.16 Billion ≈ $170.47 Million |
+27.54% |
| 2024-12-31 | CN¥913.38 Million ≈ $133.66 Million |
+79.77% |
| 2023-12-31 | CN¥508.07 Million ≈ $74.35 Million |
-32.11% |
| 2022-12-31 | CN¥748.35 Million ≈ $109.51 Million |
+6.71% |
| 2021-12-31 | CN¥701.30 Million ≈ $102.62 Million |
-27.41% |
| 2020-12-31 | CN¥966.08 Million ≈ $141.37 Million |
-23.82% |
| 2019-12-31 | CN¥1.27 Billion ≈ $185.56 Million |
-2.65% |
| 2018-12-31 | CN¥1.30 Billion ≈ $190.61 Million |
+9.89% |
| 2017-12-31 | CN¥1.19 Billion ≈ $173.45 Million |
+312.58% |
| 2016-12-31 | CN¥287.30 Million ≈ $42.04 Million |
+2.57% |
| 2015-12-31 | CN¥280.11 Million ≈ $40.99 Million |
+198.30% |
| 2014-12-31 | CN¥93.90 Million ≈ $13.74 Million |
-40.51% |
| 2013-12-31 | CN¥157.85 Million ≈ $23.10 Million |
+511.75% |
| 2012-12-31 | CN¥25.80 Million ≈ $3.78 Million |
-62.32% |
| 2011-12-31 | CN¥68.48 Million ≈ $10.02 Million |
-29.97% |
| 2010-12-31 | CN¥97.79 Million ≈ $14.31 Million |
-35.64% |
| 2009-12-31 | CN¥151.93 Million ≈ $22.23 Million |
+77.72% |
| 2008-12-31 | CN¥85.49 Million ≈ $12.51 Million |
-- |
About China Resources Boya Bio pharmaceutical Group Co Ltd
China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the research, development, production, and sale of blood products in China. It offers blood products, such as human serum albumin; human, intravenous, freeze-dried intravenous, hepatitis B, tetanus, and rabies immunoglobulin; and human fibrinogen, prothrombin complex, and coagulation factor VIII. The company also provides compound b… Read more